Colonic purgative composition with soluble binding agent
First Claim
1. A method of treating a patient with, or susceptible to, a gastrointestinal disorder comprising(a) orally administering to the patient a formulation in a solid dosage tablet form, wherein each tablet comprises between 7.5% and 15% of polyethylene glycol having an average molecular weight of 7,000 to 9,000 daltons, and about 1.5 grams of sodium phosphate, wherein the polyethylene glycol is admixed with the sodium phosphate in the tablet to maintain the tablet form, and(b) maintaining or promoting the elimination of feces in the bowel.
11 Assignments
0 Petitions
Accused Products
Abstract
This invention relates to novel colonic purgative compositions in a solid dosage form, comprising at least one purgative and at least one soluble, or soluble, nonfermentable binder, such as polyethylene glycol. Further, this invention relates to methods of using the colonic purgative compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time improving the quality of bowel cleansing. The formulations and methods of this invention are particularly useful to cleanse the bowel prior to diagnostic and surgical procedures and can also be employed in lower dosages as a laxative to promote elimination and/or to relieve constipation.
25 Citations
38 Claims
-
1. A method of treating a patient with, or susceptible to, a gastrointestinal disorder comprising
(a) orally administering to the patient a formulation in a solid dosage tablet form, wherein each tablet comprises between 7.5% and 15% of polyethylene glycol having an average molecular weight of 7,000 to 9,000 daltons, and about 1.5 grams of sodium phosphate, wherein the polyethylene glycol is admixed with the sodium phosphate in the tablet to maintain the tablet form, and (b) maintaining or promoting the elimination of feces in the bowel.
-
3. A method of treating a patient suffering from, or susceptible to, constipation due to administration of a medication comprising:
-
(a) orally administering to the patient a formulation in a solid dosage tablet form, wherein each tablet comprises between 7.5% and 15% of polyethylene glycol having an average molecular weight of 7,000 to 9,000 daltons, and about 1.5 grams of sodium phosphate, wherein the polyethylene glycol is admixed with the sodium phosphate in the tablet to maintain the tablet form; and (b) maintaining or promoting the elimination of feces in the bowel. - View Dependent Claims (4, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)
-
-
5. A method of treating a patient suffering from, or susceptible to, constipation comprising
(a) orally administering to the patient a formulation in a solid dosage tablet form, wherein each tablet comprises between 7.5% and 15% of polyethylene glycol having an average molecular weight of 7,000 to 9,000 daltons, and about 1.5 grams of sodium phosphate, wherein the polyethylene glycol is admixed with the sodium phosphate in the tablet to maintain the tablet form, and (b) maintaining or promoting the elimination of feces in the bowel, wherein the constipation is due to at least one of travel; - change in daily routine;
lack of exercise;
immobility caused by injury, illness, or aging;
dehydration;
irritable bowel syndrome;
pregnancy;
diabetes;
hypothyroidism;
hypercalcemia;
cancer of the colon or rectum;
uterine prolapse;
vaginal vault prolapse;
rectal prolapse;
scarring from surgery;
injury of the colon or rectum;
Parkinson'"'"'s disease;
multiple sclerosis;
stroke;
hemorrhoids or anal fissures;
delaying bowel movements;
anxiety;
depression;
eating disorders; and
obsessive-compulsive disorder. - View Dependent Claims (31, 32, 33, 34, 35, 36, 37, 38)
- change in daily routine;
Specification